Advice
Following a full submission.
Intravenous esomeprazole (Nexium IV®) is accepted for use within NHS Scotland for the treatment of gastroesophageal reflux disease in patients with esophagitis and/or severe symptoms of reflux as an alternative to oral therapy when oral intake is not appropriate.
Intravenous esomeprazole seems to be as effective as oral esomeprazole in terms of gastric acid suppression and healing of erosive oesophagitis. However comparisons with other IV proton pump inhibitors are restricted to pre-clinical studies. Esomeprazole has similar acquisition costs to other IV proton pump inhibitors.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Esomeprazole (Nexium®)
- SMC ID:
- 124/04
- Indication:
- Gastroesophageal reflux
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 October 2004